Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval

Yusimry Biosimilar To Humira Set For 1 July 2023 Launch, After Multiple Rivals

20 Dec 2021

As the likely dynamics for US biosimilar competition to Humira come into sharper focus, Coherus has promised that its mid-2023 market entry with its just-approved Yusimry version will be accompanied by a “compelling value proposition,” months after rival Amgen’s biosimilar is expected to launch and around the same time as multiple other rivals are expected to hit the market.

Alarm clock dollar bills money — Coherus must wait until mid-2023 to make its “compelling value proposition” • Source: Alamy

Fresh from obtaining US Food and Drug Administration approval for its Yusimry (adalimumab-aqvh) biosimilar rival to Humira, Coherus BioSciences has promised to come to market with a “compelling value proposition” when it launches from 1 July 2023 under the terms of a settlement with originator AbbVie.

Coherus’ promise for Yusimry – the firm’s second approved US biosimilar, after the successful Udenyca (pegfilgrastim-cbqv) rival to Neulasta –...